Michaela Liedtke
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Hematology
- Member, Stanford Cancer Institute
- Assistant Professor - Med Center Line (By courtesy), Pathology
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC-2332 MC 5821 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-5203
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Hematology
- Cancer> Hematology> Leukemia - Acute and Chronic
- Multiple Myeloma
- Amyloidosis
- Hematology
Administrative Appointments
- Member, Stanford Amyloid Center (2010 - present)
- Member Leukemia Committee, Southwest Oncology Group (2011 - present)
Honors and Awards
- Translational Research Award, Stanford Department of Medicine (2011)
- Young Investigator Award, ASCO (2008)
- Research grant, Hope Street Kids Foundation (2006)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Fellowship Award, Lymphoma Research Foundation (2004)
- Translational Research Award, Doris Duke Foundation (2004)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2006) |
| Board Certification: | Hematology, American Board of Internal Medicine (2005) |
| Fellowship: | Stanford University Medical Center CA (2005) |
| Fellowship: | Memorial Sloan-Kettering Cancer Center, NY USA (2004) |
| Residency: | Albert Einstein College of Medicine NY (2002) |
| Medical Education: | Medizinische Hochschule Hannover, Germany (1994) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis
4) Characterization of the molecular mechanism of MLL-induced acute leukemia
Clinical Trials
- Recruiting An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
- Not Recruiting Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma
- Recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Recruiting A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
- Recruiting A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Publications
- A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2013
- Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013; (1): 11-7
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013; (4): 591-6
- The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol. 2013; (3): 367-72
- Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2012; (10): 957-60
- Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. J Heart Lung Transplant. 2012; (3): 325-31
Help
Trial Administration